Smith & Nephew plc reported a strong finish to 2025, with underlying revenue of $6.2 billion, up 5.3 % from the prior year, and operating profit of $794 million. Trading profit rose to $1.211 billion, giving a trading margin of 19.7 % versus 18.1 % in 2024. Free cash flow surged 52.5 % to $840 million, and the company lifted its annual dividend to 39.1 cents per share. A $500 million share‑buyback was completed in the second half of the year, underscoring management’s confidence in the business and its ability to return capital to shareholders.
The three business units all grew, with Orthopaedics leading at 7.9 % underlying revenue growth, Sports Medicine & ENT at 7.3 %, and Advanced Wound Management at 2.8 %. The overall Q4 underlying revenue growth of 6.2 % reflects strong demand for new products launched in the last five years, which accounted for more than 60 % of the year‑to‑date growth.
Smith & Nephew completed its 12‑Point Plan, a transformation program that delivered significant margin expansion. The plan’s focus on operational discipline, cost control and product mix optimization helped lift the trading margin to 19.7 %. The company’s CEO, Deepak Nath, said, "I am pleased that a strong fourth quarter helped us meet or exceed our 2025 targets for revenue growth, profitability and cash generation. During the year, newer products drove strong broad‑based performance, with underlying revenue growth above 5 % for all three business units, and we look forward to a strong cadence of further new product introductions in 2026."
Management guided for 2026 underlying revenue growth of about 6 %, and a trading profit of roughly $1.3 billion, signalling confidence in the company’s ability to sustain momentum. The guidance follows the launch of the RISE strategy, which aims to "reach more patients, unlock new categories of innovation, scale through strategic investment, and execute efficiently." The company also highlighted that the 12‑Point Plan’s completion positions it to pursue new 2028 financial targets.
Investors reacted cautiously, citing modest 2026 revenue guidance, the weak 2.8 % growth in Advanced Wound Management, and concerns about the sustainability of margin expansion after a 160‑basis‑point improvement in 2025. The market’s focus on these headwinds suggests that while the 2025 results were strong, the outlook for continued acceleration remains a key concern.
"With our strengthened foundations and new strategy, we are well set to expand our leadership in healthcare innovation and realise sustainable value for shareholders, while continuing to deliver for customers, employees and communities into the future," Nath added.
"This also marks the completion of our 12‑Point Plan, through which we have successfully transformed Smith+Naphew into a fundamentally stronger business."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.